ALPN - Alpine Immune Sciences, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
4.7200
+0.1200 (+2.61%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.6000
Open4.6000
Bid4.6900 x 800
Ask4.7400 x 800
Day's Range4.5850 - 4.9289
52 Week Range3.6600 - 8.5900
Volume10,277
Avg. Volume8,933
Market Cap87.656M
Beta (3Y Monthly)2.60
PE Ratio (TTM)N/A
EPS (TTM)-2.9420
Earnings DateFeb 13, 2019 - Feb 18, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.50
Trade prices are not sourced from all markets
  • Introducing Alpine Immune Sciences (NASDAQ:ALPN), The Stock That Dropped 43% In The Last Year
    Simply Wall St.28 days ago

    Introducing Alpine Immune Sciences (NASDAQ:ALPN), The Stock That Dropped 43% In The Last Year

    The simplest way to benefit from a rising market is to buy an index fund. When you buy individual stocks, you can make...

  • Investors Who Bought Alpine Immune Sciences (NASDAQ:ALPN) Shares A Year Ago Are Now Down 43%
    Simply Wall St.28 days ago

    Investors Who Bought Alpine Immune Sciences (NASDAQ:ALPN) Shares A Year Ago Are Now Down 43%

    Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. Active...

  • Business Wire2 months ago

    Alpine Immune Sciences Appoints Biopharma Veteran Wayne Gombotz as Chief Technology Officer

    Alpine Immune Sciences, Inc. (ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the appointment of Wayne Gombotz, PhD as Chief Technology Officer. Dr. Gombotz has more than 30 years’ experience in the biotech and pharma industries and most recently served as the Chief Development Officer at Immune Design. “We are pleased to welcome Wayne, a pioneer in the field and a key contributor to the biotechnology industry here in Seattle, to Alpine,” said Stanford Peng, MD PhD, President and Head of Research and Development for Alpine.

  • Business Wire2 months ago

    Alpine Immune Sciences to Present at Upcoming Investor Conferences

    Alpine Immune Sciences, Inc. , a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the company will participate in three upcoming investor conferences in June.

  • AdaptImmune partners to advance promising cancer immunotherapies
    American City Business Journals2 months ago

    AdaptImmune partners to advance promising cancer immunotherapies

    Alpine gets $2 million from Adaptimmune now, and up to $290 million if the partnership is successful in producing next-generation cancer immunotherapies.

  • GlobeNewswire2 months ago

    Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell Products

    Adaptimmune Therapeutics plc (ADAP), a leader in T-cell therapy to treat cancer, and Alpine Immune Sciences, Inc., Seattle, WA, (ALPN), a leading immunotherapy company focused on developing treatments for autoimmune diseases and cancer, today announced a collaboration and license agreement to develop next-generation SPEAR T-cell products which incorporate Alpine’s secreted and transmembrane immunomodulatory protein (termed SIP™ and TIP™) technology. This collaboration will further enhance Adaptimmune’s efforts to design and develop next-generation SPEAR T-cell therapies. “SPEAR T-cell therapies have demonstrated clinical promise for the treatment of solid tumors.

  • Earnings Preview: Alpine Immune Sciences (ALPN) Q1 Earnings Expected to Decline
    Zacks2 months ago

    Earnings Preview: Alpine Immune Sciences (ALPN) Q1 Earnings Expected to Decline

    Alpine Immune Sciences (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Have Insiders Been Buying Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Shares?
    Simply Wall St.3 months ago

    Have Insiders Been Buying Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Shares?

    We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares. So shareholders might...

  • Business Wire3 months ago

    Alpine Immune Sciences Appoints Stanford Peng to President and Head of Research and Development

    Alpine Immune Sciences, Inc. (ALPN) (“Alpine”), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced Stanford Peng, M.D. Ph.D., has been appointed President and Head of Research and Development of Alpine, effective April 16, 2019. Dr. Peng, who served as Alpine’s Executive Vice President of Research & Development and Chief Medical Officer since 2016, succeeds Mark Litton, Ph.D., whose role as President and Chief Operating Officer ended effective April 16, 2019.

  • The Zacks Analyst Blog Highlights: CMS Energy, Alpine Immune Sciences, Kohl's, Franklin Resources and Dominion Energy
    Zacks3 months ago

    The Zacks Analyst Blog Highlights: CMS Energy, Alpine Immune Sciences, Kohl's, Franklin Resources and Dominion Energy

    The Zacks Analyst Blog Highlights: CMS Energy, Alpine Immune Sciences, Kohl's, Franklin Resources and Dominion Energy

  • 5 Best Stocks to Buy Ahead of Q1 Earnings Season
    Zacks3 months ago

    5 Best Stocks to Buy Ahead of Q1 Earnings Season

    Total earnings for the S&P 500 companies are estimated to drop 4% from the same period last year, which would be the first quarterly decline since 2016. Revenues are expected to rise 4.6%.

  • Will Nivalis Therapeutics Continue to Surge Higher?
    Zacks4 months ago

    Will Nivalis Therapeutics Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor in Nivalis Therapeutics.

  • The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy
    Zacks4 months ago

    The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy

    The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy

  • Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy
    Zacks4 months ago

    Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy

    Smaller drugmakers are having a relatively better 2019 than their larger counterparts. Here are seven stocks to buy.

  • Business Wire4 months ago

    Alpine Immune Sciences Provides Corporate Update and Reports Full Year 2018 Financial Results

    SEATTLE-- -- First Subjects Dosed in Phase I Clinical Trial for Lead Autoimmune/Inflammatory Disease Program, ALPN-101 Completed $25 Million Private Placement Strong Financial Position to Transition Two Lead Programs ALPN-101 and ALPN-202 into Patients Alpine Immune Sciences, Inc. , a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, ...

  • Top Ranked Momentum Stocks to Buy for March 15th
    Zacks4 months ago

    Top Ranked Momentum Stocks to Buy for March 15th

    Top Ranked Momentum Stocks to Buy for March 15th

  • Business Wire5 months ago

    Alpine Immune Sciences to Present at Two Upcoming Investor Conferences

    Alpine Immune Sciences, Inc. , a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the company will participate in two upcoming investor conferences in March.

  • Business Wire5 months ago

    Alpine Immune Sciences Presents Preclinical ALPN-101 GvHD Data at the 2019 Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR (TCT Meetings)

    Alpine Immune Sciences, Inc. (ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced it will present preclinical GvHD data from its ALPN-101 program at the 2019 Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR (TCT Meetings) in Houston, TX. Additionally, Alpine has strengthened its Scientific Advisory Board with the addition of immunotherapy scientific veteran Vijay Kuchroo, DVM, PhD.

  • Business Wire5 months ago

    Alpine Immune Sciences Announces First Subjects Dosed in Phase I Clinical Trial for Lead Autoimmune/Inflammatory Disease Program ALPN-101

    Alpine Immune Sciences, Inc. (ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced successful initiation of dosing in its first-in-human Phase I study of ALPN-101, a first-in-class dual ICOS/CD28 antagonist. In addition, pharmacokinetics, pharmacodynamics, and exploratory biomarkers are being evaluated to help determine ALPN-101’s potential for the treatment of autoimmune and inflammatory diseases. “This first dosing in the initial clinical trial of ALPN-101 is an important milestone for Alpine as we have now transitioned to a clinical-stage development company,” stated Mitchell H. Gold, MD, Executive Chairman and Chief Executive Officer of Alpine.

  • GuruFocus.com6 months ago

    Alpine Immune Sciences Inc (ALPN) Executive Chairman and CEO Mitchell Gold Bought $1 million of ...

    Executive Chairman and CEO of Alpine Immune Sciences Inc (NASDAQ:ALPN) Mitchell Gold bought 190,875 shares of ALPN on 01/18/2019 at an average price of $5.37 a share.

  • Business Wire6 months ago

    Alpine Immune Sciences Announces $25 Million Private Placement

    Alpine Immune Sciences, Inc. (ALPN), a leading immunotherapy company dedicated to developing innovative treatments for patients suffering from cancer and autoimmune/inflammatory diseases, today announced it has entered into a definitive securities purchase agreement for the sale of units consisting of shares of common stock and warrants to purchase common stock, as described below, in a private placement expected to result in gross proceeds to the Company of approximately $25.3 million, before deducting placement agent commissions and other offering expenses. The private placement is being led by Decheng Capital with participation from existing investors OrbiMed Advisors, Frazier Healthcare Partners, Alpine BioVentures, and BVF Partners L.P. Effective on the closing of the private placement, the Company expects to appoint Min Cui, Ph.D., Founder and Managing Director of Decheng Capital, to the Alpine Board of Directors.

  • GlobeNewswire7 months ago

    Angion Completes Equity Financing and Appoints Senior Executives

    Closes $35 million financing to advance Phase 2 and Phase 3 programs with drug candidate ANG-3777Announces appointments of Jay R. Venkatesan, M.D. as President and Chief.

  • Business Wire8 months ago

    Alpine Immune Sciences Showcases Key Preclinical Data at 60th American Society of Hematology Annual Meeting and Exposition

    Alpine Immune Sciences, Inc. (ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced positive results from multiple preclinical studies which were presented at the American Society of Hematology’s (ASH) 60th Annual Meeting & Exposition in San Diego, CA. Oral and poster presentations described promising efficacy of ALPN-101 in preclinical models of acute graft versus host disease (GvHD) and hemophagocytic lymphohistiocytosis (HLH), while a poster presentation described the company’s transmembrane and secreted immunomodulatory protein (TIP/SIP) platform to enhance the activity of engineered T cell therapies for cancer.

  • Business Wire8 months ago

    Alpine Immune Sciences Announces ALPN-101 Data to be Included in Oral Presentation at 60th American Society of Hematology Annual Meeting and Exposition

    Alpine Immune Sciences, Inc. , a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced pre-clinical data from its lead autoimmune/inflammatory program, ALPN-101, will be included in an oral presentation at the 60th American Society of Hematology Annual Meeting and Exposition on Sunday, December 2, 2018 at 9:30am ...